Psilocybin clears biggest depression test yet, but Compass stock falls amid chatter about adverse events, durability

This article discusses some of the findings from the COMP360 in which patients with treatment-resistant depression were administered psilocybin with psychological support. The trial was ran by Compass Pathways and is the largest trial to date with psilocybin.